热景生物(688068)每日收评(03-26) 热景生物688068 时间: 2025年3月26日星期三 59.65分综合得分 较强 趋势方向 主力成本分析 85.01 元 87.47 元 5日主力成本 81.88 元 20日主力成本 70.59 元 当日主力成本 60日主力成本 周期内涨跌停 过去一年内该股 涨停 2次 跌停 0 次 技术面分析 91.33 短期压力位 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 2025年03月26日的资金流向数据方面 83.18 短期支撑位 93.30 中期压力位 57.32 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 | 主力资金净流入120.65万元 | | --- | | 占总成交额1% | | 超大单净流入375.33万元 | | 大单净流出254.68万元 | | 散户资金净流出24.91万 | 关联行业/概念板块 医疗器械 0.74%、食品安全 1.62%、国家安防 0.70%、体外诊断 0.51%等 财务数据 最近的财报数据显示，该股于2 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-019 北京热景生物技术股份有限公司（以下简称"公司"）及子公司近期获得境外 资质认证 30 项。相关信息如下： 一、获得资质的具体情况 （一） 获得境外认证情况 | 序号 | 产品中文名称 | 产品英文名称 | 注册证号 | 分类 | 获批日期 | 有效期至 | 发证 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | （备案号） | | | | 国家 | | 1 | 铁蛋白测定试 剂盒（磁微粒化 | Ferritin test (Chemiluminescence | No.V12 089675 0009 | Class B | 2025/3/18 | 2029/9/11 | 欧盟 | | | 学发光免疫分 | Immunoassay) | | | | | | | | 析法） | | | | | | | | 2 | 白介素 2 受体测 定试剂盒（磁微 | Interleukin-2 Receptor test | No.V12 089675 0009 | Class B | ...

证券代码：688068 证券简称：热景生物 公告编号：2025-018 北京热景生物技术股份有限公司股东减持股份 计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，北京热景生物技术股份有限公司（以下简称"公司"） 股东青岛同程热景企业管理咨询合伙企业（有限合伙）（以下简称"同程热景"） 持有公司股份 4,211,357 股，占公司股份总数的 4.55%，股份来源于公司首次公 开发行前持有及资本公积转增股本取得，已上市流通。 减持计划的主要内容 公司近日收到股东同程热景发出的《关于减持公司股份的告知函》。因自身 资金需求，股东同程热景计划通过集中竞价、大宗交易方式减持所持有公司股份 合计不超过 1,800,000 股，占公司总股本的 1.9465%。 依据《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、监 事、高级管理人员减持股份》相关规定：任意连续 90 日内，股东采取集中竞价 交易方式减持股份的总数不得超过公司股份总数的 1%；采取 ...

北京热景生物技术股份有限公司 股票交易异常波动公告 证券代码：688068 证券简称：热景生物 公告编号：2025-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）股票于 2025 年 3 月 5 日、2025 年 3 月 6 日、2025 年 3 月 7 日连续三个交易日内日收盘价格涨幅 偏离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板 股票异常交易实时监控细则》（以下简称"《实时监控细则》"）的有关规定，属于 股票交易异常波动情形。 经公司自查并书面询证公司控股股东及实际控制人，截至本公告披露日， 公司不存在应披露而未披露的重大事项。 利润亏损的风险：根据公司披露的 2024 年度业绩快报，2024 年度实现 归属于母公司所有者的净利润-17,923.07 万元，与去年同期相比下降 728.52%； 实现归属于母公司所有者的扣除非经常性损益的净利润-24,315.82 万元，与去 年同期相比下降 317.82%。 联营企 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-016 北京热景生物技术股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 3 月 6 日 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司三层会议室 是 （五） 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：关于增加公司经营范围暨修订《公司章程》并办理工商变更登记 的议案 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 109 | | --- | --- | | 普通股股东人数 | 109 | | 2、出席会议的股东所持有的表决权数量 | 41,870,531 | | 普通股股东所持有表决权数量 | 41,87 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 康达股会字【2025】第 0046 号 二〇二五年三月 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称"《规则》"）、《北 京热景生物技术股份有限公司章程》（以下简称"《公司章程》"）及北京热景生物技术 股份有限公司（以下简称"公司"）与北京市康达律师事务所（以下简称"本所"）签 订的法律顾问协议，本所律师对公司 2025 年第一次临时股东大会（以下简称"本次 会议"或"本次股东大会"）进行见证并出 ...

Summary of the Conference Call for 热景生物 (Rejane Biotech) Company Overview - 热景生物 is transitioning from its core IVD (In Vitro Diagnostics) business to the innovative drug sector through its subsidiaries: 顺景医药, 窑井基因, and 于景药业, focusing on areas such as cardiac-targeted small nucleic acid technology, small nucleic acid drugs, and gastrointestinal probiotics [2][3][6] Core Products and Innovations - The core product SGC001 monoclonal antibody targets acute myocardial infarction (AMI) by inhibiting the inflammatory response mediated by S100A8/A9 proteins, potentially delaying myocardial cell death and improving patient outcomes, especially significant given over 1 million AMI cases annually in China [2][7][11] - SGC001 is designed for early administration during AMI, filling a treatment gap between onset and PCI (Percutaneous Coronary Intervention), aiming to control inflammation and reduce complications [2][12][13] - The company is also developing other innovative drugs, including dual-antibody ADCs, expected to enter clinical trials by 2025 [3] Early Screening and Detection - 热景生物 is actively developing microRNA test kits for early cancer screening, including for pancreatic, gastric, liver, urinary tract, and prostate cancers, with the 小薇安 kit for liver cancer achieving world-leading sensitivity and specificity [4][5] - The integration of AI diagnostic technology enhances the accuracy of liver cancer risk prediction models, potentially increasing market acceptance [4] Financial Performance and Market Potential - Since its establishment in 2005 and listing on the Sci-Tech Innovation Board in 2019, 热景生物 has shown steady performance and is currently in a rapid transformation phase, focusing on innovative drug development [6][24] - The market potential for its drugs is substantial, with estimates suggesting a domestic market size of 5-6 billion RMB and a potential overseas market reaching 10 billion USD [4][22][23] Clinical Trials and Research Collaborations - Ongoing clinical trials for SGC001 involve ST-segment elevation AMI patients, with safety and preliminary efficacy being key observation metrics [21] - Collaborations with renowned institutions, such as 安贞医院, enhance research capabilities and accelerate the clinical translation of new diagnostic markers and therapeutic targets [8][9] Unique Drug Design Features - The drug design features a short half-life, aligning with the biological characteristics of S100A8/A9, and preclinical studies using rhesus monkey models have shown promising results in reducing myocardial infarction area and improving sequential scores [20] Management Team - The management team, led by Chairman 林长青 and Chief Scientist 孙志伟, has a strong scientific background and has successfully guided the company through its transition to innovative pharmaceuticals [10] Conclusion - 热景生物 is positioned for significant growth in the innovative drug market, with a strong pipeline of products and a focus on addressing critical healthcare needs, particularly in the treatment of acute myocardial infarction and cancer detection [24]

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook based on its innovative pipeline and potential in the heart failure market [5][65]. Core Insights - The company has a rich pipeline of innovative drugs, particularly the SGC001 antibody for acute myocardial infarction, which is expected to fill a significant clinical gap and has substantial domestic and international market potential [6][49]. - The company is actively expanding its innovative pipeline through subsidiaries focusing on nucleic acid drugs, antibody drugs, and probiotics, which are in various stages of development [7][20]. - The company has established itself as a leading brand in POCT (Point of Care Testing) and is integrating diagnostic and therapeutic strategies, particularly in the field of acute myocardial infarction [7][18]. Summary by Sections Market Performance - As of February 28, 2025, the closing price is 67.30 CNY, with a total market capitalization of 6,223.55 million CNY [3]. Financial Forecast - The company is projected to generate total revenues of 5.11 billion CNY in 2024, 6.02 billion CNY in 2025, and 7.08 billion CNY in 2026, with year-on-year growth rates of -5.61%, 17.85%, and 17.55% respectively [8][63]. - The net profit attributable to the parent company is expected to be -1.77 billion CNY in 2024, -0.68 billion CNY in 2025, and 0.43 billion CNY in 2026 [8][65]. Business Strategy - The company is leveraging its expertise in POCT to explore innovative drug development, establishing a multi-omics diagnostic technology platform and expanding into antibody and exosome drug fields [18][19]. - The SGC001 drug, developed for acute myocardial infarction, has received dual approval for clinical trials in both the US and China, highlighting its potential as a first-in-class treatment [48][49]. Competitive Position - The company is compared with peers in the POCT sector, such as Wanfu Biology and Jiuan Medical, indicating a stable POCT business and promising growth in innovative drug development [8][65].

证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 2 月 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 4 | | 2025 | 年第一次临时股东大会会议议案 | 6 | 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司股东大会规则》以及《北京热景生物技术股份有限公司章程》、《北京热景生物 技术股份有限公司股东大会议事规则》等相关规定，北京热景生物技术股份有限公司 （以下简称"公司"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员 将对出席会议者的身份进行必要的核对工 ...

Financial Performance - The total operating revenue for 2024 was 51,089.06 million CNY, a decrease of 7.62% compared to the previous year[4] - The net profit attributable to the parent company was -17,923.07 million CNY, a decline of 728.52% year-on-year[4] - The basic earnings per share fell by 725.81% to -1.94 CNY[5] - The company experienced a 317.82% increase in net profit attributable to the parent company after excluding non-recurring gains and losses, totaling -24,315.82 million CNY[4] - The weighted average return on equity decreased by 6.55 percentage points to -5.70%[5] Assets and Equity - The total assets at the end of the reporting period were 330,909.69 million CNY, down 7.35% from the previous year[5] - The equity attributable to the parent company decreased by 8.49% to 308,144.19 million CNY[5] Research and Development - The R&D investment for 2024 reached 11,276.71 million CNY, accounting for 22.07% of the operating revenue[7] - The company reported an investment loss of 4,763.16 million CNY from joint ventures due to increased R&D expenditures[7] Impairment and Competition - A total of 8,478.31 million CNY was recognized as impairment losses on operating assets due to intensified industry competition[7]